| [1] |
Song Z, Zou K, Zou L. Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: an update on clinical data[J]. Front Oncol, 2022, 12: 1045481. DOI: 10.3389/fonc.2022.1045481.
|
| [2] |
Gennigens C, Jerusalem G, Lapaille L, et al. Recurrent or primary metastatic cervical cancer: current and future treatments[J]. ESMO Open, 2022, 7(5): 100579. DOI: 10.1016/j.esmoop.2022.100579.
|
| [3] |
李英, 程忠平. 复发性宫颈癌免疫治疗的研究进展[J]. 中国妇产科临床杂志, 2023, 24(1): 108-110. DOI: 10.13390/j.issn.1672-1861.2023.01.041.
|
| [4] |
孙敬兰, 戴建荣. 宫颈癌免疫治疗的临床研究进展[J]. 医学综述, 2022, 28(16): 3204-3210.
|
| [5] |
Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2 pathway from discovery to clinical implementation[J]. Front Immunol, 2016, 7: 550. DOI: 10.3389/fimmu.2016.00550.
|
| [6] |
Bevins NJ, Okamura R, Montesion M, et al. Tumor infiltrating lymphocyte expression of PD-1 predicts response to anti-PD-1/PD-L1 immunotherapy[J]. J Immunother Precis Oncol, 2022, 5(4): 90-97. DOI: 10.36401/JIPO-22-9.
pmid: 36483582
|
| [7] |
Wang LL, Li ZH, Hu XH, et al. The roles of the PD-1/PD-L1 pathway at immunologically privileged sites[J]. Am J Reprod Immunol, 2017, 78(2): 12710. DOI: 10.1111/aji.12710.
|
| [8] |
Li W, Wu F, Zhao S, et al. Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: a key player in tumor immunotherapy[J]. Cytokine Growth Factor Rev, 2022, 67: 49-57. DOI: 10.1016/j.cytogfr.2022.07.004.
|
| [9] |
Yang Y, Wang X, Bai Y, et al. Programmed death-ligand 2 (PD-L2) expression in bladder cancer[J]. Urol Oncol, 2020, 38(6): 603.e9-603.e15. DOI: 10.1016/j.urolonc.2020.01.001.
|
| [10] |
Rotman J, den Otter LAS, Bleeker MCG, et al. PD-L1 and PD-L2 expression in cervical cancer: regulation and biomarker potential[J]. Front Immunol, 2020, 11: 596825. DOI: 10.3389/fimmu.2020.596825.
|
| [11] |
Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2018, 392(10142): 123-133. DOI: 10.1016/S0140-6736(18)31257-1.
pmid: 29880231
|
| [12] |
Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2019, 37(17): 1470-1478. DOI: 10.1200/JCO.18.01265.
|
| [13] |
杨钧媛, 蔡红兵. 宫颈癌免疫治疗的耐药机制及应对措施[J]. 肿瘤防治研究, 2022, 49(9): 886-892. DOI: 10.3971/j.issn.1000-8578.2022.22.0162.
|
| [14] |
Vesely MD, Zhang T, Chen L. Resistance mechanisms to anti-PD cancer immunotherapy[J]. Annu Rev Immunol, 2022, 40: 45-74. DOI: 10.1146/annurev-immunol-070621-030155.
pmid: 35471840
|
| [15] |
O'Malley DM, Neffa M, Monk BJ, et al. Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase Ⅱ study[J]. J Clin Oncol, 2022, 40(7): 762-771. DOI: 10.1200/JCO.21.02067.
|
